250 related articles for article (PubMed ID: 23386251)
21. Competitive inhibition of SGLT2 by tofogliflozin or phlorizin induces urinary glucose excretion through extending splay in cynomolgus monkeys.
Nagata T; Suzuki M; Fukazawa M; Honda K; Yamane M; Yoshida A; Azabu H; Kitamura H; Toyota N; Suzuki Y; Kawabe Y
Am J Physiol Renal Physiol; 2014 Jun; 306(12):F1520-33. PubMed ID: 24761001
[TBL] [Abstract][Full Text] [Related]
22. TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity.
Yamamoto K; Uchida S; Kitano K; Fukuhara N; Okumura-Kitajima L; Gunji E; Kozakai A; Tomoike H; Kojima N; Asami J; Toyoda H; Arai M; Takahashi T; Takahashi K
Br J Pharmacol; 2011 Sep; 164(1):181-91. PubMed ID: 21410690
[TBL] [Abstract][Full Text] [Related]
23. Cardiac ischemia-reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity.
Yoshii A; Nagoshi T; Kashiwagi Y; Kimura H; Tanaka Y; Oi Y; Ito K; Yoshino T; Tanaka TD; Yoshimura M
Cardiovasc Diabetol; 2019 Jul; 18(1):85. PubMed ID: 31262297
[TBL] [Abstract][Full Text] [Related]
24. Intestinal Sodium Glucose Cotransporter 1 Inhibition Enhances Glucagon-Like Peptide-1 Secretion in Normal and Diabetic Rodents.
Oguma T; Nakayama K; Kuriyama C; Matsushita Y; Yoshida K; Hikida K; Obokata N; Tsuda-Tsukimoto M; Saito A; Arakawa K; Ueta K; Shiotani M
J Pharmacol Exp Ther; 2015 Sep; 354(3):279-89. PubMed ID: 26105952
[TBL] [Abstract][Full Text] [Related]
25. The Na
Koepsell H
Pharmacol Ther; 2017 Feb; 170():148-165. PubMed ID: 27773781
[TBL] [Abstract][Full Text] [Related]
26. Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences.
Gallo LA; Wright EM; Vallon V
Diab Vasc Dis Res; 2015 Mar; 12(2):78-89. PubMed ID: 25616707
[TBL] [Abstract][Full Text] [Related]
27. Development of SGLT1 and SGLT2 inhibitors.
Rieg T; Vallon V
Diabetologia; 2018 Oct; 61(10):2079-2086. PubMed ID: 30132033
[TBL] [Abstract][Full Text] [Related]
28. Effect of LX4211 on glucose homeostasis and body composition in preclinical models.
Powell DR; DaCosta CM; Smith M; Doree D; Harris A; Buhring L; Heydorn W; Nouraldeen A; Xiong W; Yalamanchili P; Mseeh F; Wilson A; Shadoan M; Zambrowicz B; Ding ZM
J Pharmacol Exp Ther; 2014 Aug; 350(2):232-42. PubMed ID: 24849925
[TBL] [Abstract][Full Text] [Related]
29. Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo.
Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Qun L; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
Naunyn Schmiedebergs Arch Pharmacol; 2012 Apr; 385(4):423-36. PubMed ID: 22139434
[TBL] [Abstract][Full Text] [Related]
30. Development of a novel non-radioactive cell-based method for the screening of SGLT1 and SGLT2 inhibitors using 1-NBDG.
Chang HC; Yang SF; Huang CC; Lin TS; Liang PH; Lin CJ; Hsu LC
Mol Biosyst; 2013 Aug; 9(8):2010-20. PubMed ID: 23657801
[TBL] [Abstract][Full Text] [Related]
31. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models.
Fujimori Y; Katsuno K; Nakashima I; Ishikawa-Takemura Y; Fujikura H; Isaji M
J Pharmacol Exp Ther; 2008 Oct; 327(1):268-76. PubMed ID: 18583547
[TBL] [Abstract][Full Text] [Related]
32. Optimizing SGLT inhibitor treatment for diabetes with chronic kidney diseases.
Layton AT
Biol Cybern; 2019 Apr; 113(1-2):139-148. PubMed ID: 29955959
[TBL] [Abstract][Full Text] [Related]
33. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice.
Suzuki M; Honda K; Fukazawa M; Ozawa K; Hagita H; Kawai T; Takeda M; Yata T; Kawai M; Fukuzawa T; Kobayashi T; Sato T; Kawabe Y; Ikeda S
J Pharmacol Exp Ther; 2012 Jun; 341(3):692-701. PubMed ID: 22410641
[TBL] [Abstract][Full Text] [Related]
34. SGLT2 inhibition and renal urate excretion: role of luminal glucose, GLUT9, and URAT1.
Novikov A; Fu Y; Huang W; Freeman B; Patel R; van Ginkel C; Koepsell H; Busslinger M; Onishi A; Nespoux J; Vallon V
Am J Physiol Renal Physiol; 2019 Jan; 316(1):F173-F185. PubMed ID: 30427222
[TBL] [Abstract][Full Text] [Related]
35. Combined SGLT1 and SGLT2 Inhibitors and Their Role in Diabetes Care.
Danne T; Biester T; Kordonouri O
Diabetes Technol Ther; 2018 Jun; 20(S2):S269-S277. PubMed ID: 29916741
[TBL] [Abstract][Full Text] [Related]
36. Mechanistic evaluation of the effect of sodium-dependent glucose transporter 2 inhibitors on delayed glucose absorption in patients with type 2 diabetes mellitus using a quantitative systems pharmacology model of human systemic glucose dynamics.
Mori-Anai K; Tashima Y; Nakada T; Nakamaru Y; Takahata T; Saito R
Biopharm Drug Dispos; 2020 Nov; 41(8-9):352-366. PubMed ID: 33085977
[TBL] [Abstract][Full Text] [Related]
37. Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?
Liu JJ; Lee T; DeFronzo RA
Diabetes; 2012 Sep; 61(9):2199-204. PubMed ID: 22923645
[TBL] [Abstract][Full Text] [Related]
38. Clinical relevance of the selectivity of sodium-glucose cotransporter-2 inhibitors.
Morales-Olivas FJ
Med Clin (Barc); 2016 Nov; 147 Suppl 1():26-29. PubMed ID: 28760222
[TBL] [Abstract][Full Text] [Related]
39. Sotagliflozin as a potential treatment for type 2 diabetes mellitus.
Cariou B; Charbonnel B
Expert Opin Investig Drugs; 2015; 24(12):1647-56. PubMed ID: 26548423
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis and biological evaluation of 6-deoxy O-spiroketal C-arylglucosides as novel renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes.
Wang Y; Lou Y; Wang J; Li D; Chen H; Zheng T; Xia C; Song X; Dong T; Li J; Li J; Liu H
Eur J Med Chem; 2019 Oct; 180():398-416. PubMed ID: 31325786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
